(A) A schematic of the crystal structure illustrating the RING1B-PCGF4 dimer bound to E2 ubiquitin conjugating enzyme (UBCH5C) (PDB ID: 3RPG) (Bentley et al., 2011) . The key amino acids that mediate RING1B-E2 interaction are indicated. (B) A schematic illustrating how I53A or I53A/D56K mutations were introduced into the endogenous Ring1b gene in mouse ESCs (TC = targeting construct). (C) Western blot analysis of RING1B (with BRG1 as a loading control) and H2AK119ub1 (with H3 as a loading control) in RING1B WT , RING1B I53A and RING1B I53A/D56K ESCs (top panel). Quantification of H2AK119ub1 levels from the western blot analysis above (bottom panel) .
Error bars show SEM (n = 6) and the p-value denotes statistical significance calculated by a paired one-tailed Student's t-test. (D) Immunoprecipitation of RING1B from RING1B WT or RING1B I53A/D56K ESCs followed by western blot for cPRC1 and vPRC1 components as indicated. Western blot for SUZ12 (a PRC2 component) was used as a negative control. For RING1B I53A/D56K ESCs, a control IP was performed with an isotype control antibody. (A) Bar plots showing the overlap between RING1B-and SUZ12-bound genomic regions. This illustrates that PRC1 and PRC2 share a large number of target sites, with > 95% of SUZ12 peaks overlapping with RING1B peaks, while RING1B binding appears to be more broad. (B) Heatmap analysis of cChIP-seq in PRC1 CKO ESCs for RING1B , SUZ12 and H3K27me3 (untreated) at RING1B-bound sites divided into two groups based on the overlap with SUZ12 peaks (RING1B/SUZ12-bound or PcG-occupied (n = 7074) and only RING1B-bound (n = 11,569)). For each group, the genomic regions were sorted based on RING1B occupancy in untreated cells. (A) Box plots of cChIP-seq signal for RING1B, PCGF1 and PCGF6 at RING1B-bound sites divided into quartiles based on H3K27me3 levels in untreated cells (from lowest Q1 to highest Q4) in PRC1 CPM ESCs before and after OHT treatment. This shows that PCGF1 and PCGF6 occupancy is largely uniform across all RING1B-bounds sites with different H3K27me3 levels. (B) Box plots comparing changes in cChIP-seq signal for RING1B, PCGF1 and PCGF6 following OHT treatment in PRC1 CPM cells at RING1B-bound sites divided into quartiles based on H3K27me3 levels in untreated cells. Together with (A), this shows that following removal of PRC1 catalytic activity, RING1B occupancy is reduced at sites with high levels of H3K27me3 (Q3 and Q4) but is retained/increased at sites with low levels of H3K27me3 (Q1 and Q2). In addition, it demonstrates that PCGF1 and PCGF6 occupancy is only modestly affected following loss of PRC1 catalytic activity, with binding of PCGF1 slightly increased at sites with low level of H3K27me3 and binding of PCGF6 moderately reduced at sites with high enrichment of H3K27me3. (C) Box plots comparing volumes and mean intensities of RING1B-Halo-JF549 nuclear foci in PRC1 CPM ESCs before (ncells = 69) and after OHT treatment (ncells = 83). P-values denote statistical significance calculated by a Wilcoxon rank sum test. (D) Box plots comparing numbers of RING1B-Halo-JF549 nuclear foci detected in PRC1 CPM ESCs before (ncells = 69) and after OHT treatment (ncells = 83), with foci divided into quartiles based on focus volume (left) or mean intensities (right) in untreated cells (from lowest Q1 to highest Q4). This shows that loss of PRC1 catalysis had the strongest effect on RING1B nuclear foci with the largest volume and mean intensity, while the foci with low to moderate intensities/volumes remained largely unchanged or even increased. This is in agreement with changes in RING1B occupancy by cChIP-seq at target sites with different levels of RING1B binding in untreated cells. Bottom panel: Box plots comparing the gene expression levels from cRNA-seq in PRC1 CPM and PRC1 CKO ESCs before (UNT) and after OHT treatment (OHT) for three groups of derepressed genes defined in the Venn diagram above: PRC1 CKO -specific, shared between PRC1 CKO and PRC1 CPM ESCs, and PRC1 CPM -specific. This demonstrates that for the genes categorised as specifically derepressed in either PRC1 CKO or PRC1 CPM OHT-treated ESCs, the magnitude of gene expression changes is more modest than for the shared targets, making them more sensitive to the choice of a significance threshold. Importantly, expression levels of these genes following OHT treatment are highly similar between the two cell lines. (A) Box plots of PCGF2 cChIP-seq signal in PRC1 CPM cells before (UNT) and after OHT treatment (OHT) at RING1B-bound sites associated with the promoters of PRC1-repressed genes which are either partially (n = 241) or fully derepressed (n = 2241) following loss of PRC1 catalysis as compared to a complete loss of PRC1. (B) As in (A) for H3K27me3 cChIP-seq. (C) Box plots comparing sizes of RING1B-bound sites overlapping with the promoters of PRC1repressed genes which are either partially (n = 241) or fully derepressed (n = 2241) following OHT treatment in PRC1 CPM as compared to PRC1 CKO ESCs. (D) Box plots of log2 fold expression changes (cRNA-seq) for genes associated with PcG-occupied sites which show a significant reduction in SUZ12 levels following OHT treatment in PRC1 CPM cells, divided into genes that become derepressed (p-adj < 0.05 and > 1.5-fold) following loss of PRC1 catalysis (UP, n = 1766) and those that do not change in expression (NoChange, n = 1779). (E) Box plots of log2 fold changes in PRC2 (SUZ12, JARID2 and PCL2) and H3K27me3 cChIP-seq signal at promoter-proximal PcG-occupied sites which show a significant reduction in SUZ12 levels following OHT treatment in PRC1 CPM cells, divided into sites which are associated with genes that become derepressed (p-adj < 0.05 and > 1.5-fold) following loss of PRC1 catalysis (UP, n = 1766) and those that do not change in expression (NoChange, n = 1779).
